Detalhe da pesquisa
1.
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
N Engl J Med
; 385(23): 2123-2131, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34874631
2.
Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience.
Gynecol Oncol
; 162(2): 284-291, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34083029
3.
Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care.
Int J Gynecol Cancer
; 30(11): 1748-1756, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32784203
4.
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
Gynecol Oncol
; 152(1): 53-60, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30449719
5.
Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model.
Acta Oncol
; 58(6): 828-837, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30810443
6.
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Lancet Oncol
; 19(12): 1680-1687, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413383
7.
Chromatin organisation and cancer prognosis: a pan-cancer study.
Lancet Oncol
; 19(3): 356-369, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29402700
8.
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only.
Int J Gynecol Cancer
; 28(9): 1789-1795, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30365455
9.
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).
Br J Cancer
; 116(4): 455-463, 2017 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28118323
10.
Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival.
Gynecol Oncol
; 145(3): 543-548, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28356187
11.
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Gynecol Oncol
; 144(1): 65-71, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27871723
12.
Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer.
Acta Oncol
; 56(5): 675-681, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28447564
13.
A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway.
Acta Obstet Gynecol Scand
; 96(10): 1162-1169, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28795770
14.
[Properties of cancer cell DNA affects the prognosis]. / Egenskaper ved kreftcellenes DNA påvirker prognosen.
Tidsskr Nor Laegeforen
; 137(19)2017 10 17.
Artigo
em Norueguês
| MEDLINE | ID: mdl-29043733
15.
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Lancet Oncol
; 17(4): 509-518, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26952945
16.
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 17(1): 78-89, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26590673
17.
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.
Br J Cancer
; 115(2): 228-35, 2016 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27351218
18.
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
BMC Cancer
; 16: 596, 2016 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27488577
19.
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Gynecol Oncol
; 140(3): 457-62, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26807488
20.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Lancet Oncol
; 16(8): 928-36, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26115797